Lin Yi Wu

age ~92

from Walnut Creek, CA

Get Report

Also known as:

Connected to:

Lin Wu Phones & Addresses

Reduction Of Cardiovascular Symptoms
view source
US Patent:

20080153840, Jun 26, 2008
Filed:

Dec 20, 2007
Appl. No.:

11/961860
Inventors:

Luiz Belardinelli - Palo Alto CA, US
Lin Wu - Sunnyvale CA, US
Sridharan Rajamani - Fremont CA, US
Arvinder Dhalla - Mountain View CA, US
International Classification:

A61K 31/496
A61P 9/00
US Classification:

51425212
Abstract:

The present application discloses methods for treating patients with a dysfunction of the ion channels of the heart suffering from one or more cardiovascular diseases to reduce the proarrhythmic effect of drugs and/or conditions that reduce or inhibit I.

Diagnostic Test For Susceptibility To B-Raf Kinase Inhibitors
view source
US Patent:

20100173294, Jul 8, 2010
Filed:

Jul 30, 2009
Appl. No.:

12/512914
Inventors:

Rachel Langland - Oakland CA, US
Lin Wu - Moraga CA, US
Thad Sharp - Parsippany NJ, US
Stephen Will - Rotkreuz, CH
Assignee:

ROCHE MOLECULAR SYSTEMS, INC. - Pleasanton CA
International Classification:

C12Q 1/68
US Classification:

435 6
Abstract:

The present invention provides methods and reagents for the detection of a mutation in BRAF and methods of selecting patients for treatment if a B-Raf kinase inhibitor, such as a selective B-Raf kinase inhibitor

Diagnostic Test For Susceptibility To B-Raf Kinase Inhibitors
view source
US Patent:

20110212991, Sep 1, 2011
Filed:

Jan 27, 2011
Appl. No.:

13/015374
Inventors:

Rachel Langland - Oakland CA, US
Lin Wu - Moraga CA, US
Thad Sharp - Parsippany NJ, US
Stephen Will - Cham, CH
Assignee:

ROCHE MOLECULAR SYSTEMS, INC. - Pleasanton CA
International Classification:

A61K 31/437
C12Q 1/68
C07H 21/04
A61P 35/00
US Classification:

514300, 435 611, 536 2431
Abstract:

The present invention provides methods and reagents for the detection of a mutation in BRAF and methods of selecting, patients for treatment if a B-Raf kinase inhibitor, such as a selective B-Raf kinase inhibitor.

Screening Method For Agents That Modulate Human Nik Activity
view source
US Patent:

58540032, Dec 29, 1998
Filed:

Feb 26, 1998
Appl. No.:

/032475
Inventors:

Mike Rothe - San Mateo CA
Lin Wu - South San Francisco CA
Assignee:

Tularik Inc. - South San Francisco CA
International Classification:

G01N 33566
US Classification:

435 78
Abstract:

The invention provides methods and compositions relating to a novel kinase, NIK, involved in NF. kappa. B activation. The polypeptides may be produced recombinantly from transformed host cells from the disclosed NIK encoding nucleic acids or purified from human cells. The invention provides isolated NIK hybridization probes and primers capable of specifically hybridizing with the disclosed NIK genes, NIK-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.

Human Nik Proteins
view source
US Patent:

58440739, Dec 1, 1998
Filed:

Feb 13, 1998
Appl. No.:

/023321
Inventors:

Mike Rothe - San Mateo CA
Lin Wu - South San Francisco CA
Assignee:

Tularik Inc. - South San Francisco CA
International Classification:

C07K 412
C07K 706
C07K 708
C07K 1447
US Classification:

530300
Abstract:

The invention provides methods and compositions relating to a novel kinase, NIK, involved in NF. kappa. B activation. The polypeptides may be produced recombinantly from transformed host cells from the disclosed NIK encoding nucleic acids or purified from human cells. The invention provides isolated NIK hybridization probes and primers capable of specifically hybridizing with the disclosed NIK genes, NIK-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.

Nucleic Acids Encoding Human Nik Protein
view source
US Patent:

58437215, Dec 1, 1998
Filed:

Jul 3, 1997
Appl. No.:

8/887518
Inventors:

Mike Rothe - San Mateo CA
Lin Wu - South San Francisco CA
Assignee:

Tularik Inc. - South San Francisco CA
International Classification:

C12P 2106
C12N 100
C12N 510
C12N 1512
US Classification:

435 692
Abstract:

The invention provides methods and compositions relating to a novel kinase, NIK, involved in NF. kappa. B activation. The polypeptides may be produced recombinantly from transformed host cells from the disclosed NIK encoding nucleic acids or purified from human cells. The invention provides isolated NIK hybridization probes and primers capable of specifically hybridizing with the disclosed NIK genes, NIK-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.

Diagnostic Test For Susceptibility To B-Raf Kinase Inhibitors
view source
US Patent:

20170067122, Mar 9, 2017
Filed:

Nov 4, 2016
Appl. No.:

15/344364
Inventors:

- Pleasanton CA, US
Lin Wu - Moraga CA, US
Thad Sharp - Parsippany NJ, US
Stephen Will - Oakland CA, US
International Classification:

C12Q 1/68
Abstract:

The present invention provides methods and reagents for the detection of a mutation in BRAF and methods of selecting patients for treatment if a B-Raf kinase inhibitor, such as a selective B-Raf kinase inhibitor.

Egfr Blood Monitoring
view source
US Patent:

20160237507, Aug 18, 2016
Filed:

Apr 13, 2016
Appl. No.:

15/098150
Inventors:

- Pleasanton CA, US
Boe Sorensen - Beder, DK
Julie Tsai - Newark CA, US
Wei Wen - Santa Clara CA, US
Lin Wu - Moraga CA, US
International Classification:

C12Q 1/68
A61K 31/517
A61K 31/5377
Abstract:

Improved methods of assessing status of a solid-tumor cancer in a subject involving detection of tumor-associated mutations in the subject's blood.